Abstract:Osteomyelitis, an infectious disease predominantly tied to poor sanitary conditions in underdeveloped regions of the world, is in need of inexpensive, easily in situ synthesizable and administrable materials for its treatment. The results of this study stem from the attempt to create one such affordable and minimally invasive therapeutic platform in the form of a self-setting, injectable cement with a tunable drug release profile, composed of only nanoparticulate hydroxyapatite, the synthetic version of the bone mineral. Cements comprised two separately synthesized hydroxyapatite powders, one of which, HAP2, was precipitated abruptly, retaining the amorphous nature longer, and the other one of which, HAP1, was precipitated at a slower rate, more rapidly transitioning to the crystalline structure. Cements were made with four different weight ratios of the two hydroxyapatite components: 100/0, 85/15, 50/50, and 0/100 with respect to HAP1 and HAP2. Both the setting and the release rates measured on two different antibiotics, vancomycin and ciprofloxacin, were controlled using the weight ratio of the two hydroxyapatite components. Various inorganic powder properties were formerly used to control drug release, but here we demonstrate for the first time that the kinetics of the mechanism of formation of a solid compound can be controlled to produce tunable drug release profiles. Specifically, it was found that the longer the precursor calcium phosphate component of the cement retains the amorphous nature of the primary precipitate, the more active it was in terms of speeding up the diffusional release of the adsorbed drug. The setting rate was, in contrast, inversely proportional to the release rate and to the content of this active hydroxyapatite component, HAP2. The empirical release profiles were fitted to a set of equations that could be used to tune the release rate to the therapeutic occasion. All of the cements loaded with vancomycin or ciprofloxacin inhibited the growth of Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli and Pseudomonas aeruginosa in both agar diffusion assays and broth dilution tests with intensities either comparable to the antibiotic per se, as in the case of ciprofloxacin, or even larger than the antibiotic alone, as in the case of vancomycin. Interestingly, even the pure cements exhibited an antibacterial effect ranging from moderate to strong, while demonstrating high levels of biocompatibility with osteoclastic RAW264.7 cells and only slightly affecting the viability of the osteoblastic MC3T3-E1 cells, in direct proportion with the amount of the more active hydroxyapatite component in the cements. This antibacterial effect was especially noticeable against Gram-negative bacteria, where the growth inhibition by the cements was comparable to or even stronger than that of the pure antibiotics. The antibiofilm assay against P. aeruginosa biofilms reiterated the antibiotic effectiveness of pure, antibiotic-free cements. That the carrier per se, composed of a nontoxic, easily prepared, bone mineral composite, can exhibit a strong antibacterial effect even in the absence of an antibiotic drug is an insight highly relevant in view of the rising resistance of an array of pathogens to traditional antibiotic therapies and the demands for the timely development of suitable alternatives.

[Treatment of chronic osteomyelitis with antibiotic-loaded calcium phosphate cement]

Extracellular Matrix Scaffold Crosslinked with Vancomycin for Multifunctional Antibacterial Bone Infection Therapy

Hierarchical antibiotic delivery system based on calcium phosphate cement/montmorillonite-gentamicin sulfate with drug release pathways

Treatment of long bone infection by a biodegradable bone cement releasing antibiotics in human

Le Calcium Phosphate Cement Imprégné De 10 % De Vancomycine Délivre Une Haute Concentration Antibiotique Locale Précoce Et Tardive

Calcium Phosphate Cement Loaded with 10% Vancomycin Delivering High Early and Late Local Antibiotic Concentration in Vitro

Endowing Calcium Phosphate Ceramics with Long-Acting Antibacterial Capacity by Constructing Multilevel Antibiotic Release Structure for Regenerative Repair of Infected Bone Defect

The Effect of Calcium Sulfate/calcium Phosphate Composite for the Treatment of Chronic Osteomyelitis Compared with Calcium Sulfate

Carvacrol-loaded Premixed Calcium Phosphate Bone Cements with Exceptional Osteogenic and Antibacterial Properties to Heal Infected Bone Defects

Tunable Calcium Phosphate Cement Formulations for Predictable Local Release of Doxycycline

Composite Scaffold of Liposome Loaded Drug and Calcium Deficient Apatite Cement

Study on the applied properties of tobramycin-loaded calcium phosphate cement

Effect of Low-Frequency Pulsed Ultrasound on Drug Delivery, Antibacterial Efficacy, and Bone Cement Degradation in Vancomycin-Loaded Calcium Phosphate Cement

Preparation and in Vitro Releasing of Salmon Calcitonin Carried Porous Injectable Calcium Phosphate Bone Cement

Enhanced osteogenic and bactericidal performance of premixed calcium phosphate cement with photocrosslinked alginate thin film

Study on injectable silver-incorporated calcium phosphate composite with enhanced antibacterial and biomechanical properties for fighting bone cement-associated infections

Functionalized Hydroxyapatite and Curcumin Incorporated Stimuli‐Responsive Low‐Exothermic and Injectable Poly(methyl methacrylate) Bone Cement for the Treatment of Osteomyelitis

Synergistic effect of drug/antibiotic-impregnated micro/nanohybrid mesoporous bioactive glass/calcium phosphate composite bone cement on antibacterial and osteoconductive activities

Accelerating Biodegradation Of Calcium Phosphate Cement

Self-Setting Calcium Phosphate Cements with Tunable Antibiotic Release Rates for Advanced Antimicrobial Applications

Bioactive Calcium Phosphate Cement with Excellent Injectability, Mineralization Capacity and Drug-Delivery Properties for Dental Biomimetic Reconstruction and Minimum Intervention Therapy